Top 10 Questions to Ask Your Doctor About GLP-1 Lab Work

There is a pattern that plays out thousands of times a day across clinics in the United States. A patient — recently diagnosed with type 2 diabetes, obesity, or both — walks out with a prescription for semaglutide or another GLP-1 medication. They feel hopeful. They may also feel overwhelmed.

What they often do not walk out with is clarity about what lab work should accompany that prescription.

That gap matters. GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, and Zepbound — are not simple appetite suppressants. They are metabolic interventions that engage the pancreas, kidneys, liver, and thyroid, among other systems. Prescribing them without a baseline laboratory picture is the equivalent of overhauling a complex engine without first running diagnostics.

This guide gives you a concrete, clinically informed set of questions to bring to your next appointment — whether you are about to start GLP-1 therapy or are already mid-treatment and unsure what is being monitored and why.

Why Lab Work Is Not Optional on GLP-1 Therapy

Before getting into the questions themselves, some context is useful.

GLP-1 medications work through a multi-system mechanism. They enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and signal satiety through the hypothalamus. That breadth of effect is precisely what makes them so clinically powerful — and precisely why monitoring matters.

There are two distinct phases of lab assessment that every patient on GLP-1 therapy should understand:

Baseline labs are ordered before treatment begins. They establish the metabolic "before" picture — capturing kidney function, liver health, glucose control, lipid status, and thyroid function. If something goes wrong six months into treatment, a baseline panel is what allows your clinician to determine whether that change was pre-existing or treatment-related.

Monitoring labs are ordered at intervals during treatment. They track the intended effects (improved A1C, better lipids) alongside safety markers (kidney function, pancreatic enzymes).

The American Diabetes Association's Standards of Medical Care and the prescribing information for semaglutide both support comprehensive metabolic evaluation before and during treatment.[1,2] In practice, however, these evaluations are inconsistent, which is why patients who ask specific questions get better care.

The Top 10 Questions to Ask Your Doctor

Question 1: What Baseline Lab Tests Should I Get Before Starting My GLP-1 Medication?

This is the most foundational question, and asking it before your prescription is filled rather than after gives you the most clinical leverage.

A comprehensive pre-GLP-1 panel should include:

• Comprehensive Metabolic Panel (CMP): Covers kidney markers (creatinine, BUN, eGFR), liver enzymes (ALT, AST, ALP, bilirubin), electrolytes, and glucose. This is the single most information-dense starting point.
• Complete Blood Count (CBC): Provides baseline on red and white blood cell counts, which matter if fatigue or immune changes emerge later.
• Hemoglobin A1C: The 3-month glucose average; essential for establishing glycemic status before therapy and tracking improvement.
• Fasting lipid panel: Total cholesterol, LDL, HDL, and triglycerides — GLP-1s tend to improve lipid profiles, and baseline data quantifies that benefit.
• TSH (thyroid-stimulating hormone): Thyroid dysfunction is common in GLP-1 candidate populations and can significantly confound both weight response and metabolic improvement if left unaddressed.
• Lipase and amylase (pancreatic enzymes): Particularly for patients with any history of pancreatitis, gallstones, or heavy alcohol use.

For a detailed breakdown of each test and its clinical relevance, see Meto's complete guide: Labs Before Semaglutide: Complete GLP-1 Blood Work Guide (2026).

Question 2: Will You Check My A1C, and How Often Should We Monitor It?

Hemoglobin A1C is the workhorse of GLP-1 monitoring. It reflects average blood glucose over approximately three months and is the primary metric by which glycemic improvement is tracked in both diabetes management and weight loss programs.

What is worth understanding — and asking about — is not just whether your A1C is being checked, but what trajectory it is expected to follow and how quickly.

GLP-1 therapy can lower A1C meaningfully: clinical trial data from the SUSTAIN program showed average reductions of 1.0–1.8 percentage points with semaglutide, depending on dose and baseline.[3] If a patient is also on insulin or a sulfonylurea, a significant A1C drop can create hypoglycemia risk that warrants co-medication adjustment.

A reasonable monitoring cadence for most patients is:

• Every 3 months for the first year
• Every 6 months once values are stable

Ask specifically: "What A1C reduction are we targeting, and at what point would we reassess or adjust the approach?"

For context on realistic A1C changes over time, see: How Much Can A1C Drop in 3 Months?

Question 3: Should You Check My Kidney Function Before and During Treatment?

This question is underasked and clinically important. GLP-1 medications are eliminated through renal pathways, and reduced kidney function affects both drug tolerance and the risk of complications — particularly dehydration-related acute kidney injury, which can occur when GI side effects (nausea, vomiting) reduce fluid intake.

The key markers here are:

• Serum creatinine and estimated glomerular filtration rate (eGFR) — the standard measures of kidney filtration capacity
• Blood urea nitrogen (BUN) — a secondary marker that rises when the kidneys struggle
• Urine albumin-to-creatinine ratio (uACR) — especially relevant in patients with diabetes or hypertension, where early kidney damage often manifests as protein leaking into urine before eGFR declines

From a dosing standpoint, most GLP-1 prescribing information does not require dose adjustment until eGFR falls significantly, but patients with an eGFR below 60 mL/min/1.73m² warrant more frequent monitoring and clinical discussion about hydration strategy.[4]

Ask: "Based on my kidney function, are there any specific precautions I should follow, and when do we recheck these markers?"

Question 4: Do I Need a Thyroid Panel, Given the Warnings on the Label?

Most patients who read the prescribing information for semaglutide will encounter the black box warning about medullary thyroid carcinoma (MTC). This understandably raises concern. It is worth understanding what that warning actually means — and what it does not.

The MTC association was identified in rodent studies at doses substantially higher than those used clinically. No causal relationship has been established in humans to date, and population-level data from large GLP-1 user cohorts have not shown a clear increase in MTC incidence.[5] That said, there are defined contraindications: GLP-1 therapy is not appropriate for patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2 syndrome).

The practical take:

• A TSH at baseline is appropriate for most patients — not primarily for the MTC question, but because undiagnosed hypothyroidism is common and significantly blunts weight loss response
• Calcitonin testing is not routinely recommended prior to GLP-1 initiation in most guidelines, but should be discussed for patients with any thyroid nodules, neck radiation history, or family history of thyroid cancer
• Disclose any thyroid history — diagnosed or suspected — to your prescribing clinician before starting

For further reading on interpreting thyroid results: Thyroid Test Results Chart: What Your Numbers Mean

Question 5: Should My Pancreatic Enzymes (Lipase and Amylase) Be Tested?

Pancreatitis is among the most-searched GLP-1 safety concerns, and patients deserve a clear-eyed answer.

GLP-1 receptor agonists have a plausible mechanism for pancreatic involvement — they directly stimulate GLP-1 receptors present in pancreatic tissue. Post-marketing surveillance has reported cases of acute pancreatitis, and the FDA has added a warning to labeling.[6] However, the absolute risk remains low, and large observational studies have not confirmed a statistically significant increase in pancreatitis compared to other diabetes medications.

The clinical nuance:

• Routine baseline lipase/amylase is not universally mandated by guidelines, but is clinically reasonable — particularly if a patient has a history of pancreatitis, cholelithiasis (gallstones), hypertriglyceridemia, or heavy alcohol use
• Symptom-triggered testing is the standard response: any severe, persistent upper abdominal pain radiating to the back during GLP-1 therapy should prompt immediate evaluation, not a scheduled lab appointment

Ask your doctor: "Given my history, do you recommend a baseline lipase, and what symptoms should prompt me to seek immediate evaluation?"

Question 6: What Will My Cholesterol and Lipid Panel Look Like on GLP-1s?

This question often surprises newly prescribed patients — many do not expect GLP-1s to affect their cholesterol. They do, and generally favorably.

Data from the SUSTAIN and SCALE trials demonstrated that semaglutide therapy is associated with reductions in LDL cholesterol, total cholesterol, and triglycerides, alongside modest increases in HDL.[3,8] For patients already managing cardiovascular risk, this creates a meaningful opportunity: GLP-1-related lipid improvement may reduce or eliminate the need for statin therapy, but that conversation should be guided by lab data — not assumptions.

Key considerations:

• Run a fasting lipid panel at baseline, then re-check at 3 months and annually thereafter
• Elevated triglycerides at baseline are clinically significant — they may indicate underlying insulin resistance or early hepatic dysfunction, both of which affect GLP-1 response
• Do not adjust statin dosing independently based on perceived improvement; let the follow-up numbers drive that clinical conversation

For context on understanding your lipid numbers: Cholesterol Levels Explained

Question 7: How Will You Monitor My Liver Health While I'm on This Medication?

The intersection of GLP-1 therapy and liver health is more nuanced than most patients realize — and more clinically relevant.

A large proportion of GLP-1 candidates present with non-alcoholic fatty liver disease (NAFLD), now more precisely termed metabolic-associated fatty liver disease (MAFLD). GLP-1 receptor agonists have shown promising effects on hepatic steatosis in clinical studies, making them potentially therapeutic for this condition as well.[9] However, rapid weight loss — one of the well-known effects of GLP-1 therapy — is also a known risk factor for gallstone formation, a point that deserves explicit discussion with your physician.

Monitoring framework:

• ALT and AST at baseline and at 6-month intervals — modest elevation (less than 3× the upper limit of normal) may be chronic and pre-existing; significant or rapid elevation warrants investigation
• For patients with known or suspected fatty liver disease, a FIB-4 score (calculated from ALT, AST, age, and platelet count) can help stratify fibrosis risk non-invasively
• If gallstone risk is elevated — particularly in rapid responders with significant early weight loss — discuss whether ultrasound surveillance or ursodeoxycholic acid prophylaxis is appropriate

Ask: "Do you have any concern about my liver function specifically, and should we track gallstone risk given how quickly I'm losing weight?"

Question 8: Are There Any Vitamin or Nutrient Deficiencies I Should Watch For?

This is the question that most clinicians do not raise proactively — and most patients do not think to ask. It is also one of the more practically important aspects of long-term GLP-1 management.

The mechanism is straightforward: GLP-1 medications markedly reduce appetite and caloric intake. Sustained caloric restriction, even when clinically intended, can lead to micronutrient insufficiencies that compound fatigue, cognitive fog, and muscle loss — side effects that are often misattributed to the medication itself.

Nutrients to specifically ask about:

• Vitamin B12: Reduced food intake, especially in patients previously on metformin (which independently impairs B12 absorption), increases deficiency risk. Deficiency manifests as fatigue, peripheral tingling, and cognitive changes.[10]
• Vitamin D: Inadequacy is highly prevalent at baseline in GLP-1 candidate populations and plays a direct role in insulin sensitivity and immune function
• Iron: Appetite suppression reduces iron-containing food consumption; women of reproductive age and patients with prior anemia are at higher risk
• Electrolytes (potassium, magnesium): Persistent GI side effects — particularly vomiting — can deplete both; low magnesium can worsen insulin resistance
• Protein adequacy: GLP-1-induced weight loss carries a risk of lean mass loss alongside fat loss. Ask whether your provider wants to monitor a nutrition marker like prealbumin, or whether a referral to a registered dietitian is appropriate

Ask: "Should we check my micronutrient levels at baseline, and do you recommend any supplements given my reduced appetite?"

Question 9: How Often Should I Come In for Follow-Up Lab Work?

This question establishes expectations and prevents the common pitfall of patients assuming that labs are a one-time event at prescription.

Unscheduled lab visits should be triggered by: persistent severe nausea or vomiting, unusual fatigue, significant swelling in lower extremities, vision changes, or abdominal pain not consistent with typical GI side effects.

Also worth asking: "Who manages my lab monitoring going forward — you, my endocrinologist, or my primary care provider?" In multi-provider settings, this question prevents labs from slipping through the cracks.

Question 10: Are There Any Labs That Could Indicate I Should Stop or Pause My GLP-1?

This is the informed patient's most important question. Understanding the red-flag thresholds is not alarmist — it is responsible self-advocacy.

Clinical signals that may warrant dose reduction, treatment pause, or discontinuation:

• Declining eGFR / rising creatinine: A sustained drop in eGFR or a creatinine increase of >0.3 mg/dL from baseline, particularly with concurrent vomiting and dehydration, warrants immediate clinical evaluation
• Significantly elevated lipase (>3× upper normal): Especially if accompanied by abdominal pain — this should prompt acute pancreatitis workup, not a scheduled clinic visit
• Rising calcitonin: If thyroid monitoring is in place, rising calcitonin levels warrant endocrinology referral
• Severe hypokalemia or electrolyte abnormality: More likely in patients with significant ongoing GI symptoms; can cause cardiac and neuromuscular consequences if untreated
• Persistently elevated transaminases: ALT or AST consistently above 3× the upper limit of normal, particularly with new-onset jaundice or right upper quadrant pain, requires GLP-1 hold and hepatology evaluation

Ask specifically: "What lab values would make you recommend stopping or pausing my medication, and what are the signs I should not wait for an appointment to report?"

3 Bonus Questions Most Patients Forget to Ask

1. "Should my other medications be adjusted based on my lab results?" 

GLP-1s do not operate in isolation. If you are on insulin, a sulfonylurea, a diuretic, or metformin, your doses may need recalibration as your glucose, weight, and kidney function change. This conversation should happen proactively — not after a hypoglycemic episode.

2. "Do my labs look different because of my age, kidney baseline, or other conditions?"

Reference ranges are population averages. A fasting glucose of 99 mg/dL looks different in a 28-year-old versus a 64-year-old with stage 2 CKD. Ask your provider to interpret your results in the context of your full clinical picture.

3. "Can I get a copy of my results and have you walk me through what's flagged and what's not?" 

Patient access to lab data improves adherence, trust, and self-management. You are entitled to your results, and a provider who reviews them with you — rather than just clearing them electronically — is providing a qualitatively different level of care.

Meto's Perspective: Why Pre-GLP-1 Lab Work Needs a Better Standard

At Meto, we encounter a recurring pattern among newly prescribed patients: a genuine desire to do this right, without a clear pathway to do so.

The conversation around GLP-1 lab work has historically belonged to the clinician's side of the desk. Patients rarely knew what to ask, and the variability in pre-treatment evaluation has been notable — some patients receive comprehensive panels before starting; many receive none.

We think that gap should close. Not because GLP-1s are dangerous medications — they have among the most robust cardiovascular safety and efficacy data of any metabolic therapy available — but because understanding your baseline metabolic state before a significant pharmacological intervention simply produces better outcomes. Full stop.

This is why Meto has developed purpose-built pre-GLP-1 panels that consolidate every recommended biomarker — kidney function, liver markers, A1C, fasting insulin, lipid profile, thyroid, and inflammatory markers — into a single, streamlined lab order. There is no chasing down four separate requisitions from two different providers. You get a complete metabolic snapshot, reviewed by a clinician, with clear next-step recommendations built in.

For patients already on GLP-1 therapy without a baseline, our metabolic panels serve as a mid-treatment reference point. It is not too late to establish where you are — particularly if you are experiencing side effects that could benefit from clinical context.

Get your own answers — order labs directly →

Frequently Asked Questions

What blood tests are done before starting Ozempic? 

The core pre-treatment panel includes a comprehensive metabolic panel (kidney and liver function), HbA1c, fasting glucose, a fasting lipid panel, and TSH. Clinicians may also add fasting insulin, lipase, vitamin B12, and inflammatory markers depending on the patient's history.

Does semaglutide affect kidney function? 

Directly, semaglutide has not been shown to harm kidneys — and cardiovascular outcome data suggests potential kidney-protective effects in patients with type 2 diabetes.[11] Indirectly, GI side effects that cause dehydration can strain renal function in patients with pre-existing impairment. Kidney markers should be monitored before and during treatment.

Do you need labs to get prescribed Ozempic? 

There is no universal legal requirement, but clinical guidelines from the ADA and most major medical societies recommend comprehensive metabolic evaluation before initiating GLP-1 therapy. Starting without labs is clinically suboptimal and creates avoidable risk.

What labs should be monitored on Wegovy? 

The monitoring framework is the same as for semaglutide generally: HbA1c at 3 and 6 months; comprehensive metabolic panel (kidney and liver) at similar intervals; lipid panel at 6 months; and nutritional markers (B12, D, iron) annually or sooner if symptoms suggest deficiency.

Can GLP-1 medications cause liver problems? 

GLP-1s have generally shown hepatic benefit in patients with fatty liver disease. Liver enzymes may transiently fluctuate, and rapid weight loss can increase gallstone risk — a hepatic-adjacent concern worth monitoring. Significant liver enzyme elevation during GLP-1 therapy warrants clinical evaluation.

How often should you get bloodwork on semaglutide? 

Every three months for the first year to track A1C and metabolic markers, then semi-annually once values stabilize. Unscheduled labs should be triggered by symptoms — not calendar alone.

What should I tell my doctor before starting a GLP-1? 

Full medication list (especially insulin, metformin, sulfonylureas, diuretics), any personal or family history of pancreatitis, gallstones, thyroid cancer or MEN2, existing kidney or liver diagnoses, and current supplement use. Relevant also: recent weight changes, alcohol use history, and any prior gastrointestinal conditions.

Closing Thought

A prescription for semaglutide or another GLP-1 is, at its best, the beginning of a structured metabolic intervention — not a standalone solution handed over at the pharmacy counter. The lab work that accompanies it is not bureaucratic overhead. It is the diagnostic infrastructure that makes the treatment actually work for you as an individual, rather than for an average patient in a clinical trial.

The ten questions in this guide give you the language to have that conversation confidently. Your clinician may already be planning many of these assessments — but in a visit structure that often runs fifteen minutes, the questions that get asked are the ones that get answered.

Ask them.

Related reading on Meto:

• Labs Before Semaglutide: Complete GLP-1 Blood Work Guide (2026)
• How Much Can A1C Drop in 3 Months? (Real Results + Clinical Data)
• Understanding Insulin Resistance: Signs, Tests & What to Do
• Cholesterol Levels and Numbers Explained
• Prescription Weight Loss Program at Meto
• Metabolic Fatty Liver: Clinical Overview